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Background: Hip fractures are very painful leading to lengthy hospital stays. Conventional methods of treating pain
are limited. Non-steroidal anti-inflammatories are relatively contraindicated and opioids have significant side effects.
Regional anaesthesia holds promise but results from these techniques are inconsistent. Trials to date have been
inconclusive with regard to which blocks to use and for how long. Interpatient variability remains a problem.
Methods/Design: This is a single centre study conducted at Queen’s Medical Centre, Nottingham; a large regional
trauma centre in England. It is a pragmatic, parallel arm, randomized controlled trial. Sample size will be 150
participants (75 in each group). Randomization will be web-based, using computer generated concealed tables
(service provided by Nottingham University Clinical Trials Unit). There is no blinding. Intervention will be a femoral
nerve block (0.5 mls/kg 0.25% levo-bupivacaine) followed by ropivacaine (0.2% 5 ml/hr−1) infused via a femoral
nerve catheter until 48 hours post-surgery. The control group will receive standard care. Participants will be aged
over 70 years, cognitively intact (abbreviated mental score of seven or more), able to provide informed consent,
and admitted directly through the Emergency Department from their place of residence. Primary outcomes will
be cumulative ambulation score (from day 1 to 3 postoperatively) and cumulative dynamic pain scores (day 1 to 3
postoperatively). Secondary outcomes will be cumulative dynamic pain score preoperatively, cumulative side
effects, cumulative calorific and protein intake, EUROQOL EQ-5D score, length of stay, and rehabilitation outcome
(measured by mobility score).
Discussion: Many studies have shown the effectiveness of regional blockade in neck of femur fractures, but the
techniques used have varied. This study aims to identify whether early and continuous femoral nerve block can be
effective in relieving pain and enhancing mobilization.Trial registration.
Trial registration: The trial is registered with the European clinical trials database Eudract ref: 2010-023871-25.
(17/02/2011). ISRCTN: ISRCTN92946117. Registered 26 October 2012.
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Hip fractures remain one of the most serious injuries
that occur in older people [1-3], with a mortality rate of
10% at one month, 20% at four months and 30% at one
year [4]. Many of those who recover suffer a loss in
mobility and independence. Approximately half of pa-
tients who were previously functionally independent be-
come partly dependent, while one third become totally
dependent [5]. The mean age of these patients is 81
years, 75% are female, and they are one the frailest
groups of patients to be admitted to hospital, commonly
with multiple co-morbidities. Hip fractures are painful
[6], in both the pre and postoperative period. Adequate
treatment of pain is not only a humanitarian issue, but
may also impact on recovery. Pain is associated with in-
creased neuro-hormonal stress response, myocardial
ischemia, and delayed mobilization, all of which may in-
crease postoperative length of stay and are associated
with increased postoperative mortality. Untreated pain is
also associated with delirium [7,8]. Current methods of
providing analgesia include: paracetamol, non-steroidal
anti-inflammatory drugs (NSAIDS), oral or parenteral
opioids, and regional anaesthesia techniques. Paraceta-
mol is an effective and safe analgesic [9], but insufficient
for a significant number of patients when used alone.
NSAIDs are largely contraindicated in this patient group
due to their nephrotoxicity, and gastrointestinal side ef-
fects. They may also increase operative blood loss.
Opioids provide reasonable analgesia at rest but are
relatively ineffective for dynamic pain (pain on move-
ment). This is an issue postoperatively as patients often
feel comfortable at rest but complain of moderate to se-
vere pain during physiotherapy and ambulation. Opioid-
related side effects are very common, distressing, and
potentially serious. Nausea, vomiting, constipation, and
delayed gastric emptying are common. Less common
but more serious side effects include, delirium, respira-
tory depression, and death. Regional anaesthesia offers
an attractive alternative to systemic opioids both for pre
and postoperative use. Evidence from elective lower limb
arthroplasty suggests that postoperative nerve block an-
algesia is beneficial overall [10] and may even enhance
early mobilization, assuaging concern that impairment
of motor function leads to a delay in ambulation [11].
However, to date, trials have been inconclusive regarding
the benefit in acute hip fracture patients [12,13].
Several factors may explain this. Firstly, the historical
success rate of regional anaesthetic techniques appears
to have been relatively low. A non-randomized study of
fascia iliaca block by Emergency Department physicians
found adequate block at 1 hour in only 30% of subjects,
although improvements in outcome (length of stay) were
favorable in those with a successful block [12]. Use of
ultrasound would be expected to improve the successrate of regional techniques and evidence does support
this [14]. A recent trial comparing ultrasound-guided
femoral nerve block to parenteral opioids in an Emer-
gency Department setting in exactly this patient group
demonstrated significantly reduced pain scores and de-
creased the need for rescue analgesia [15].
Another reason for the conflicting evidence is that
most studies have provided a single injection nerve
block either on admission or in the immediate peri-
operative period. Given that the pain experienced follow-
ing hip fracture persists for several days, single injection
nerve blocks may be inadequate as they only provide an-
algesia for up to 24 hours. There are two potential op-
tions to improve the duration of analgesia. Foss et al.
[16] reported the successful use of low dose continuous
epidural analgesia. Unfortunately this is not thought to
be feasible or optimal in the United Kingdom at present
for this group of patients. Another option is to provide
initial analgesia with a single shot nerve block followed
by continuous perineural infusion of local anaesthetic.
One study which used postoperative perineural catheter
infusion failed to show benefit [5], however, catheters were
only inserted postoperatively. We therefore propose to
study the effects of early and continuous femoral nerve
block analgesia on dynamic pain and early rehabilitation
compared to standard analgesic care.Methods/Design
Primary aims
The primary aim of this study is to investigate if early
use of femoral nerve blockade, with subsequent insertion
of a femoral nerve catheter and an infusion of local an-
aesthetic, results in an increase in cumulative mobility
score and a decrease in cumulative dynamic pain score
in the first three postoperative days after surgery for a
fractured neck of femur.Secondary aims
To investigate the early use of femoral nerve block re-
sults in a decrease in cumulative pain score (in the first
180 minutes of admission), a decrease in cumulative side
effects (Nausea, vomiting, constipation and delirium) in
the first three days post operatively, a decrease in overall
length of stay, better calorific and protein intake and im-
proved health related quality of life.Study design
This is a pragmatic, parallel arm, randomized controlled
trial. The setting will be Queen’s Medical Centre
Nottingham, a university teaching hospital and regional
trauma centre in England.
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There is no blinding and investigators and patients will be
aware of their treatment group allocation. ‘Sham’ block
and catheter insertion carries risks without analgesic bene-
fit and as such was considered unethical. Randomization
will take place in the Emergency Department as soon as
patients have given verbal consent to take part in the trial.
Randomization will be via password protected web-based
randomization service provided by Nottingham University
Clinical Trials Support Unit.
Selection and withdrawal of patients
Recruitment
Patients presenting to the hospital with a suspected neck
of femur fracture will be approached by a member of the
Emergency Department staff, informed of the study, and
referred to the research team for screening.
Inclusion criteria
Patients will be included if they are aged over seventy
years old, previously resident in their own home, cogni-
tively intact, previously independently mobile indoors
and willing and able to give informed consent [17].
Exclusion criteria
Patients will be excluded if the were hospitalized at the
time of fracture, have contraindications to femoral nerve
blockade, are taking regular pre fracture opioids or glu-
cocorticoids, have a history of alcohol or other substance
abuse, have a documented serious adverse reaction to
morphine, will have restrictions to their post operative
mobilisation or are already participating in another clin-
ical trial. Patients who, in the opinion of the investigator,
have any condition which would adversely affect the
study may also be excluded.
Informed consent
Patients will be assessed by the investigators regarding
ability to give informed consent. An abbreviated mental
test will be performed and patients scoring less than
seven (out of ten) will be excluded. An acute hip fracture
is extremely painful, therefore it is considered unethical
to delay immediate treatment. Patient consent will be
undertaken in two stages.
Stage 1
Subjects will be verbally informed of the exact nature of
the study; the implications and constraints of the proto-
col; the known side effects; and any risks involved in tak-
ing part. It will be clearly stated that the participant is
free to withdraw from the study at any time, for any rea-
son, without prejudice to future care and with no obliga-
tion to give the reason for withdrawal. Verbal consentwill be taken in the presence of at least one witness and
recorded in writing in the medical notes.
Stage 2
At 48 hours following administration of the nerve block
or standard analgesia, patients will be asked to give writ-
ten informed consent to continue with the trial. The
participant must personally sign and date the latest
approved version of the informed consent form. The
person obtaining consent will be a qualified and experi-
enced member of the research team. A copy of the
signed informed consent will be given to the participants
and the original signed form retained within the study
file. In an instance where the patient loses capacity to
consent during the study, the researchers will ask for
written informed consent from the next of kin (or if
there is no next of kin the orthopedic consultant under
whom the patient is currently treated). The proxy must
personally sign and date the latest approved version of
the proxy informed consent form.
Study intervention
Participants will be randomized into one of two arms:
femoral nerve block followed by insertion of a femoral
catheter and continuous femoral nerve blockade until 48
hours postoperatively; or standard analgesic care.
The femoral nerve block will be administered in the
Emergency Department by the research anaesthetic fel-
low under ultrasound guidance (0.5 ml/kg−1 of 0.25%
levo-bupivacaine up to 30 ml maximum volume). Imme-
diately after radiographic confirmation of the fracture
the participant will be transferred to the anaesthetic
suite for insertion of femoral nerve catheter. Local an-
aesthetic will be infused using an elastomeric pump.
This is a small plastic container housing an elastomeric
bag containing the local anaesthetic. The elastic recoil of
the bag drives the local anaesthetic through a resistor at
a constant rate. The pump is small and light and does
not require electrical power. The pump will contain
0.2% ropivacaine infusing at rate of 5 ml/hr-1; the dose of
local anaesthetic to be used is based on local experience
to provide analgesia without excessive motor block.
Problems related to the pump or femoral catheter will
be referred to the anaesthetic research fellow. In
addition, subjects will be prescribed paracetamol (1 g)
and tramadol (50 to 100 mg) every 6 hours. Break-
through pain will be treated with oral morphine liquid
(10 to 20 mg) every four hours.
Standard analgesic care
In the Emergency Department, participants will receive
intravenous morphine titrated to a visual analogue score
of five or less at rest. Regular paracetamol (1 g every 6
hours) and tramadol (50 to 100 mg every 6 hours) will
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oral morphine liquid (10 to 20 mg every four hours) as
required. The dose and duration of the tramadol will be
reviewed daily postoperatively and decreased according
to patient tolerance.
Concomitant medication
Patients who are on regular pre-fracture opioid therapy will
be excluded. Pre-fracture medication will be reviewed by
the orthogeriatrician and continued or amended as clinic-
ally appropriate for the individual patient. Medication
started while in hospital will be decided by the attending
orthogeriatrician as required by the patient’s condition.
Non-steroidal anti-inflammatory drugs are only used in ex-
ceptional circumstances in this group of patients at our
institution.
Concomitant treatments
The type of anaesthesia will be at the discretion of the
attending anaesthetist on the day of surgery. Common
practice at our institution is to place a femoral nerve
block either to facilitate patient positioning for a spinal
anaesthetic or as postoperative analgesia in patients hav-
ing general anaesthesia. This will be permitted in pa-
tients in the control group, however catheter insertion is
not. If the patient is in the intervention group the block
may be augmented using the catheter prior to surgery.
Standard care
Standard care will otherwise be identical in both groups
in accordance with national guidelines and standards
[18,19]. All patients are admitted to dedicated trauma
wards and cared for under a hip fracture pathway. This
includes rapid assessment and admission from the Emer-
gency Department, intravenous fluids from the time of
admission, assessment by orthogeriatricians, operation
within 36 hours of admission, assessment of bone health
and falls, multi-professional care, and discharge plan-
ning. Operations are performed in dedicated trauma the-
atres by consultants or senior trainees in anaesthesia and
orthopedic trauma.
Statistics
Data will be collected and inputted into an electronic
database by the research team. Analysis will be per-
formed by the trial statistician, using the latest version of
IBM© SPSS© Statistics software (Copyright IBM Cor-
poration 2012). There will be no interim analysis.
Sample size and justification
Based on mean cumulative postoperative mobility (CAS)
score, and mean cumulative postoperative dynamic pain
score from the study by Foss et al. [16], and standard de-
viations estimated by the formula ‘range/6’, for the CASoutcome measure, a sample size of 37 participants per
group would be required to detect a 2 point difference
in mean scores between the nerve block and standard
analgesic group (2 point difference shown to be associ-
ated with a change in postoperative length of stay), as-
suming a two-sided significance level of 0.05 and 80%
power. For the cumulated pain score, a sample size of 67
participants per group would be required to detect a 2.5
point difference in mean scores between the two groups,
using a 10 point pain scale (1 point difference shown to
be statistically significant in the study by Foss et al. [16],
using a 4 point pain scale).
Recruiting 75 patients per arm, allows a detection of a
1.5 point difference in the CAS score and 2.5 point dif-
ference in the cumulative pain score, with a 10% attri-
tion rate, assuming a two-sided significance level of 0.05
and 80% power.Definition of datasets analyzed
The safety set will comprise all randomized participants
who receive femoral nerve block or are randomized to
standard treatment. The full analysis set will comprise
all randomized participants. The per-protocol set will
comprise all participants in the full analysis set who are
deemed to have no major protocol violations that could
interfere with the objectives of the study.Reporting of adverse events
Patients will be seen daily while in the study. All adverse
events will be recorded and closely monitored until reso-
lution or stabilization, or until it has been shown that
the study intervention is not the cause. The chief investi-
gator will be informed immediately of any serious ad-
verse events and shall determine the seriousness and
causality in conjunction with any treating medical prac-
titioners. All treatment-related serious adverse events
will be recorded and reported to the research ethics
committee as part of annual reporting. Unexpected ser-
ious adverse events will be reported to the ethics com-
mittee and sponsor within the relevant time frames. The
chief investigator will be responsible for all adverse event
reporting.Ethics committee and regulatory approval
The trial received ethical approval from Nottingham
Research Ethics Committee on 28 January 2011. (Refer-
ence 10/H0408/113). The trial is funded by NIHR
Project Number: PB-PG-0909-19114. The trial will be
conducted in accordance with the Declaration of
Helsinki 1996, principles of good clinical practice, and
the Department of Health Research Governance Frame-
work for Health and Social Care.
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There seems little doubt that regional analgesia is effective
[11,15,16], however, uncertainty remains surrounding the
optimal regional anaesthetic technique and its timing.
The popularity and development of ultrasound guid-
ance in regional anaesthesia has demonstrated that block
effectiveness can be increased [14] and that these blocks
can be placed relatively quickly. Many studies, including
the one by Haines et al. [14], placed their blocks after
radiological confirmation of fracture. While this may
seem a sensible approach many patients do experience
severe pain during movement of the fractured limb in
the X-ray department. This was reinforced in the 2011
UK NICE guidelines:
‘It must be remembered that patients may require
more analgesia for investigations such as X-Rays.’ [19]
This is why, for our study, randomization and initial
block occurs before the patient has any radiological
intervention. This does, however, raise different issues.
Firstly, inserting a nerve block for a patient whose
X-rays subsequently reveal no hip fracture. This has the
potential to precipitate an admission to hospital. Sec-
ondly, it is possible to miss patients who present atypic-
ally, and are later revealed to have a hip fracture.
Both these issues would need addressing if this inter-
vention were to be implemented as standard practice.
Regarding the first scenario, for trial purposes, patients
who have no hip fracture are excluded from further ana-
lysis. We are aware of a few patients who have been
found not to have an overt hip fracture. Some have frac-
tures of the pubic ramus or acetabulum instead, and are
not suitable for discharge as their mobility is signifi-
cantly compromised and they are in significant pain. A
small number have required admission for further inves-
tigation of subtle radiographic abnormalities. In this
situation block insertion has not delayed discharge.
Due to the requirement to place the initial block
quickly we have divided our consent into two stages.
Witnessed verbal consent prior to initial block place-
ment, followed by written consent after 48 hours. This
has occasionally resulted in patients giving verbal con-
sent initially but then becoming drowsy or confused
postoperatively and being unable to sign a formal writ-
ten consent. In these instances we have retained the pa-
tients in their allocation on an intention-to-treat basis
and obtained proxy consent from a relative. While full
formal consent from the beginning should be the gold
standard we felt that delaying initial analgesia would be
unethical. Also we believe that development of delirium
pragmatically reflects the behaviour of this cohort of
patients. Not providing analgesia can also have similar
consequences [7].Dislodgement of catheters is a problem with continu-
ous nerve blockade. For our study we took the pragmatic
approach that if the catheter became dislodged within
24 hours of operation then it would be re-sited, but
beyond this the patient would be moved to standard
care. They would remain in the intervention group on
an intention-to-treat basis. We believe that this reflects
realistic practice at our unit and others.
Trial status
The study is currently ongoing. The first patient was
randomized on 6 January 2012. A total of 120 partici-
pants have been recruited so far, with an estimated com-
pletion date of June 2014.
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